Latest Global Markets News

Proteomics International Laboratories has appointed David Morris as CEO and Managing Director, marking a strategic shift towards commercialising its Promarker® diagnostic technology. Morris brings extensive global healthcare leadership experience to lead the company’s next growth phase.

NeuroScientific Biopharmaceuticals reports encouraging clinical responses in fistulising Crohn’s disease patients treated under Australia’s Special Access Scheme, setting the stage for pivotal Phase 2 trials later this year.

White Energy’s subsidiary BCBC has clinched an exclusive global agency agreement with Komarek to market briquettor machines using its proprietary BCB technology starting January 2026. This deal extends White Energy’s foothold in coal upgrading amid evolving energy markets.

BPH Global has refined its Project 6-7 R&D program to concentrate on recovering gold and silver from seaweed, aiming to fast-track commercialisation of this innovative bio-mining approach.

Ansell Limited announces the retirement of CEO Neil Salmon after five years in the role, appointing Nathalie Ahlström as his successor to lead the company’s next phase of growth and innovation.

Montaka Global Fund – Active ETF (ASX – MOGL) has announced a distribution of 10.80 cents per unit for the quarter ending 31 December 2025, alongside details of its Distribution Reinvestment Plan and tax status.

Vanguard Investments Australia has announced final distribution amounts and key dates for 27 of its ETFs, with payments scheduled for mid-January 2026. Investors can also participate in the Distribution Reinvestment Plan across all funds.

AdAlta Limited and its subsidiary AdCella have partnered with Shanghai Cell Therapy Group to co-develop a pioneering CAR-T cancer therapy targeting solid tumours outside China. This collaboration aims to bring a novel, armored immunotherapy with promising clinical results to global markets.

Hansen Technologies has completed its acquisition of UK-based Digitalk for approximately A$66.4 million, a move expected to immediately enhance its earnings and strengthen its foothold in the communications software sector.

Unith Ltd has strengthened its financial footing by securing a $1 million unsecured facility and receiving initial R&D tax refunds from Spain, validating its advanced AI platform and supporting its growth ambitions.

Invion Limited’s partner Hanlim Pharm, backed by South Korea’s government grant, has secured up to A$2 million in non-dilutive funding to advance preclinical studies of HL270 for oesophageal cancer, paving the way for human trials in Australia.

Little Green Pharma welcomes a landmark US Executive Order directing cannabis rescheduling, a move poised to reshape the global medicinal cannabis landscape.